The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Impact of lamivudine-based antiretroviral therapy on hepatitis B virus(HBV)resistance mutations among HIV/HBV coinfected patients
Author(s): 
Pages: 407-409+432
Year: Issue:  6
Journal: Chinese Journal of AIDS & STD

Keyword:  HBVHIVLamivudine(3TC)Drug resistance;
Abstract: Objective To evaluate the impact of lamivudine(3TC)based combination antiretroviral therapy(ART)on the hepatitis B viral(HBV)resistance mutations in HIV/HBV coinfected individuals.Methods 19 human immunodeficiency viral(HIV)/HBV coinfected individuals were included,who were treated with lamivudine based combination antiretroviral therapy and having HBV DNA>1000copies/mL at baseline.Mutational analysis of the RT-region was done by sequencing followed by genotyping.HBV resistance mutations at baseline and after 48 weeks of ART were analyzed.Results At baseline,no HBV resistance were detected in 5nave patients.Six of 14 experienced patients had HBV with lamivudine resistance mutations.After 48 weeks,none of nave patients and 8experienced patients was with HBV DNA higher than 1000copies/mL.Four patients developed new resistance mutations.Conclusion 3TC based ART is effective for HBV in HIV/HBV coinfected nave patients in short-term.TDF and 3TC based ART should be used for long term treatment for HIV/HBV coinfection.
Related Articles
loading...